WO2000040273A3 - Treatment of viral diseases using an interferon omega expressing polynucleotide - Google Patents

Treatment of viral diseases using an interferon omega expressing polynucleotide Download PDF

Info

Publication number
WO2000040273A3
WO2000040273A3 PCT/US1999/030843 US9930843W WO0040273A3 WO 2000040273 A3 WO2000040273 A3 WO 2000040273A3 US 9930843 W US9930843 W US 9930843W WO 0040273 A3 WO0040273 A3 WO 0040273A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral diseases
interferon omega
expressing polynucleotide
polynucleotide
Prior art date
Application number
PCT/US1999/030843
Other languages
French (fr)
Other versions
WO2000040273A8 (en
WO2000040273A2 (en
Inventor
Suezanne Parker
Holly Horton
Original Assignee
Vical Inc
Suezanne Parker
Holly Horton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc, Suezanne Parker, Holly Horton filed Critical Vical Inc
Publication of WO2000040273A2 publication Critical patent/WO2000040273A2/en
Publication of WO2000040273A3 publication Critical patent/WO2000040273A3/en
Publication of WO2000040273A8 publication Critical patent/WO2000040273A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method of treating a viral disease comprising administering to a mammal a polynucleotide construct comprising a polynucleotide encoding IFNφ. The polynucleotide construct of the present invention can be administered free from associated with transfection facilitating agents or as a complex with at least one or more cationic lipids.
PCT/US1999/030843 1999-01-08 1999-12-28 Treatment of viral diseases using an interferon omega expressing polynucleotide WO2000040273A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11540399P 1999-01-08 1999-01-08
US60/115,403 1999-01-08

Publications (3)

Publication Number Publication Date
WO2000040273A2 WO2000040273A2 (en) 2000-07-13
WO2000040273A3 true WO2000040273A3 (en) 2000-11-16
WO2000040273A8 WO2000040273A8 (en) 2001-01-11

Family

ID=22361168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030843 WO2000040273A2 (en) 1999-01-08 1999-12-28 Treatment of viral diseases using an interferon omega expressing polynucleotide

Country Status (1)

Country Link
WO (1) WO2000040273A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
US20020197235A1 (en) 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
DE60237721D1 (en) * 2001-11-09 2010-10-28 Intarcia Therapeutics Inc COMBINATION THERAPY WITH OMEGA INTERFERON FOR THE TREATMENT OF HEPATITIS C VIRUS OR YELLOW VIRUS INFECTIONS
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2351527T3 (en) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc TWO-PIECE FLOW MODULATOR WITH INTERNAL DUCT FOR AN OSMOTIC ADMINISTRATION SYSTEM.
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2013095755A (en) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd Cationic lipid
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (en) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc IMPLANT PLACEMENT AND REMOVAL SYSTEMS
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
CA3197650A1 (en) * 2020-10-02 2022-04-07 Celsion Corporation Polynucleotide vaccines and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204A2 (en) * 1984-08-01 1986-02-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic sequences, type I interferon peptide coded by them, and these organisms producing the same
WO1996017063A1 (en) * 1994-11-28 1996-06-06 Vical Incorporated Plasmids suitable for il-2 expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204A2 (en) * 1984-08-01 1986-02-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Genetic sequences, type I interferon peptide coded by them, and these organisms producing the same
WO1996017063A1 (en) * 1994-11-28 1996-06-06 Vical Incorporated Plasmids suitable for il-2 expression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 17 December 1998 (1998-12-17), AULT A: "FDA approves two new hepatitis therapies.", XP002144217, Database accession no. PREV199900076805 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, KOKOREVA L N ET AL: "Clinico-morphological characterization and effectiveness of interferon therapy in patients with chronic hepatitis delta.", XP002144216, Database accession no. PREV199497368940 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1997 (1997-10-01), HUANG CHIU-CHING: "Hepatitis in patients with end-stage renal disease.", XP002144218, Database accession no. PREV199800049222 *
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 12, no. 9-10, October 1997 (1997-10-01), pages S236 - S241, ISSN: 0815-9319 *
LANCET (NORTH AMERICAN EDITION), vol. 352, no. 9145, 17 December 1998 (1998-12-17), pages 1996, ISSN: 0099-5355 *
RAZ EYAL ET AL: "Systemic immunological effects of cytokine genes injected into skeletal muscle.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 90, no. 10, 1993, 1993, pages 4523 - 4527, XP002144215, ISSN: 0027-8424 *
ZHURNAL MIKROBIOLOGII EPIDEMIOLOGII I IMMUNOBIOLOGII, no. 1, 1994, pages 55 - 59, ISSN: 0372-9311 *

Also Published As

Publication number Publication date
WO2000040273A8 (en) 2001-01-11
WO2000040273A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
WO2000040273A8 (en) Treatment of viral diseases using an interferon omega expressing polynucleotide
WO2001081405A3 (en) Methods and compositions for the prevention and treatment of anemia
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
IL153442A0 (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
EP1758998A4 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
WO1999003508A3 (en) METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
WO1999002143A3 (en) Medicament comprising adenosine
WO2001026639A3 (en) Pharmaceutical composition of ateglinide and another antidiabeticagent
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
NZ513087A (en) Bactericidal/permability -increasing protein (BPI) for treating chronic heart disease
WO1999021538A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
AU5155700A (en) Gene therapy of pulmonary disease
WO2001094570A3 (en) Transfection method
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
WO2001075021A3 (en) A novel polypeptide, glucose transport-associated human protein 10 and the polynucleotide encoding the polypeptide
WO2002038188A3 (en) Use of the human lrp/mvp promotor for a vector that can be induced by therapy
WO2001068693A8 (en) A novel polypeptide, human cannabinoid receptor protein 7 and the polynucleotide encoding thereof
HK1056117A1 (en) Treatment of hepatitis C with thymosin and pegylated interferon
WO2001075056A3 (en) A novel polypeptide, human light-chain clathrine 20 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
122 Ep: pct application non-entry in european phase